We won't start the trial unless some BP partners with us or we get sufficient funds; filing those Phase 2 studies is a cheap way to enhance the value of the company during all on-going negotiations. This argument has been brought forward one hundred times now.
The CTC count of a single TNBC patient will not be disclosed due to FDA regulations; only data of a couple of patients are permitted to be disclosed.
I believe someone checked in with IR, and IR stated that the FDA would not permit the company to publicize the results for one patient in an expanded access protocol.
Take that for what it's worth, but I am not expecting any update on CTC in the TNBC trial until they have 5 patients enrolled in the naive (i.e., main) protocol.
News 
Market Data 
Discover 
